- Home
- CREV vs CERO Comparison
CREV vs CERO Comparison
Compare CREV & CERO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CREV
- CERO
- Stock Information
- Founded
- CREV 2007
- CERO 2017
- Country
- CREV Ireland
- CERO United States
- Employees
- CREV N/A
- CERO N/A
- Industry
- CREV
- CERO
- Sector
- CREV
- CERO
- Exchange
- CREV Nasdaq
- CERO Nasdaq
- Market Cap
- CREV 7.2M
- CERO 8.4M
- IPO Year
- CREV N/A
- CERO N/A
- Fundamental
- Price
- CREV $2.76
- CERO $0.96
- Analyst Decision
- CREV Strong Buy
- CERO
- Analyst Count
- CREV 1
- CERO 0
- Target Price
- CREV $39.00
- CERO N/A
- AVG Volume (30 Days)
- CREV 25.5K
- CERO 473.6K
- Earning Date
- CREV 01-01-0001
- CERO 03-25-2025
- Dividend Yield
- CREV N/A
- CERO N/A
- EPS Growth
- CREV N/A
- CERO N/A
- EPS
- CREV N/A
- CERO N/A
- Revenue
- CREV $39,261,077.00
- CERO N/A
- Revenue This Year
- CREV $40.76
- CERO N/A
- Revenue Next Year
- CREV $86.18
- CERO N/A
- P/E Ratio
- CREV N/A
- CERO N/A
- Revenue Growth
- CREV 41.52
- CERO N/A
- 52 Week Low
- CREV $2.00
- CERO $0.93
- 52 Week High
- CREV $22.34
- CERO $376.00
- Technical
- Relative Strength Index (RSI)
- CREV 34.70
- CERO 26.37
- Support Level
- CREV $2.72
- CERO $1.26
- Resistance Level
- CREV $3.79
- CERO $1.54
- Average True Range (ATR)
- CREV 0.22
- CERO 0.15
- MACD
- CREV -0.02
- CERO 0.06
- Stochastic Oscillator
- CREV 4.30
- CERO 3.51
About CREV Carbon Revolution Public Limited
Carbon Revolution PLC is an Australian-based technology company manufacturing carbon fiber wheels. It is an OEM supplier and a world-wide manufacturer of lightweight technology carbon fibre wheels to the automotive industry. The Company supplies wheels to OEMs across the globe for luxury and high-performance vehicles and SUVs, and is developing wheels for electric vehicles under contract for its OEM customers. The company generates maximum revenue Internationally.
About CERO CERo Therapeutics Holdings Inc. Common Stock
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T-cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy.